Medpace vs Qiagen
Medpace reported revenue of $2.5 billion in fiscal 2025, 1.2 times Qiagen's $2.1 billion in fiscal 2025. Medpace's revenue grew 20.0% in its latest year, and Qiagen's grew 5.7%. Medpace had an operating margin of 21.1%, against 22.3% at Qiagen. Free cash flow was $682 million at Medpace and $453 million at Qiagen.
Side by side
| Medpace | Qiagen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2.5B | $2.1B |
| Revenue growth | 20.0% | 5.7% |
| Revenue growth a year, last 5 years | 22.3% | 2.2% |
| Gross margin | — | 62.2% |
| Operating margin | 21.1% | 22.3% |
| Net margin | 17.8% | 20.3% |
| Free cash flow | $682M | $453M |
| Free cash flow margin | 26.9% | 21.7% |
| Return on capital | — | 9.9% |
| Net debt to EBITDA | −0.9x | 0.8x |
| Dividends and buybacks | $917M | $334M |
| Change in diluted share count | −7.8% | −2.6% |
| Last close | $633.98 | $49.63 |
| P/E at the last close | 35.2× | — |
| Insider trades, last 12 months | sold $358.9 million | — |
| Piotroski F-score | 4 of 8 | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
MedpaceQiagen
Operating margin
Percent of revenue
MedpaceQiagen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
MedpaceQiagen